Value Sense
RGEN
Repligen Corporation (RGEN)
Last Price$155.4(2.4%)
Market Cap$8,979.7M
LTM P/E
(433.2x)
EPS growth
65.1%
PEGY
(6.7x)
Peter Lynch Fair Value
($23.3)
Overvalued (Peter Lynch formula)
(115.0%)
Stock quality
6/10
Good
RGEN
is 80.8% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

RGEN Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 10, 2025
LTM P/E
(433.2x)
EPS growth
65.1%
Dividend Yield
0.0%
PEGY
(6.7x)
Last share price
$155.4
Peter Lynch Fair Value
($23.3)
115% overvalued

Peter Lynch Fair Value Calculation

PEGY
(6.7x)
=
LTM P/E
(433.2x)
/
(
EPS growth
65.09%
+
Dividend yield
0.00%
)
Peter Lynch
Fair Value
($23.3)
=
Last share price
$155.4
/
PEGY
(6.7x)

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

RGEN EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

RGEN vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Repligen Corporation logo
Repligen CorporationRGEN
(115.0%)
(21.1%)
(80.9%)
5.6%
Median Peer Set
3.4%
23.0%
10.4%
Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
71.7%
4.2%
18.3%
8.4%
ResMed Inc. logo
ResMed Inc.RMD
(16.7%)
10.9%
13.4%
21.8%
Intuitive Surgical, Inc. logo
Intuitive Surgical, Inc.ISRG
(78.8%)
17.2%
27.7%
27.8%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
6.1%
8.4%
32.2%
10.1%
West Pharmaceutical Services, Inc. logo
West Pharmaceutical Services, Inc.WST
(58.3%)
(1.9%)
(15.5%)
17.0%
Alcon Inc. logo
Alcon Inc.ALC
(37.2%)
8.5%
182.9%
10.3%
Hologic, Inc. logo
Hologic, Inc.HOLX
(7.9%)
(0.0%)
81.1%
19.6%
AptarGroup, Inc. logo
AptarGroup, Inc.ATR
(62.9%)
2.7%
30.2%
10.5%
Masimo Corporation logo
Masimo CorporationMASI
(319.6%)
0.6%
(42.5%)
4.0%
Baxter International Inc. logo
Baxter International Inc.BAX
N/A
(69.5%)
(100.0%)
(6.9%)

Explore more intrinsic value tools hub for RGEN

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Repligen Corporation fair value by Peter Lynch formula?

As of Mar 03, 2025, Repligen Corporation's fair value using the Peter Lynch formula is ($23.3) per share. The current price of $155.4 suggests Repligen Corporation may be overvalued by this metric.

What is Repligen Corporation Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Repligen Corporation's P/E ratio is (433.2x). This is calculated by dividing the current share price of $155.4 by the Earnings per Share (EPS) for the trailing twelve months, which is ($0.0). The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Repligen Corporation earnings per share (EPS)?

Repligen Corporation earnings per share (EPS) for the twelve months ending Mar 03, 2025, was ($0.0), a 65.1% growth year-over-year.